GSK to nearly double cancer medicines in clinical trials next year
Signage is pictured in the main lobby of GSK offices in London, Britain, Feb 20, 2025. (Photo: REUTERS/Chris J. Ratcliffe)
Read a summary of this article on FAST.
Get bite-sized news via a new
cards interface. Give it a try.
Click here to return to FAST
Tap here to return to FAST
FAST
LONDON: GSK said on Tuesday (Oct 27) that it expects to almost double the number of cancer medicines it has in clinical trials next year, including those in early-stage studies, as it tries to rebuild its oncology business.
The drugmaker’s clinical-stage portfolio of about 15 assets would likely “come close to doubling” in 2027, Hesham Abdullah, who heads GSK’s oncology research and development, told the Wall Street Journal earlier on Tuesday.
The British drugmaker has bet big on cancer drugs under CEO Luke Miels, including its US$10.6 billion takeover of US biotech Nuvalent earlier this year. One of the drugs acquired in the process received approval in July while a regulatory decision on another is expected by November.
Miels faces the task of reassuring investors that the company can navigate looming patent cliffs for its blockbuster HIV drugs.
Guess Word
Crack the word, one row at a time
Buzzword
Create words using the given letters
Mini Sudoku
Tiny puzzle, mighty brain teaser
Mini Crossword
Small grid, big challenge
Word Search
Spot as many words as you can
“We may have close to 20 phase threes ongoing in 2027,” Eric Richards, who heads oncology product development at GSK, told Reuters earlier in the week at a medical meeting.
Cancer drugs such as ris-rez and mo-rez are at the centre of GSK’s ambitions. On Monday, data from GSK and Hansoh’s ris-rez showed that it helped patients with a hard-to-treat cancer live longer without the disease worsening.
Five late-stage studies for mo-rez are ongoing as are two of four planned late-stage trials for ris-rez.
Cancer drugs contributed £1.08 billion (US$1.44 billion) to GSK’s first-half sales. The company is due to report third-quarter earnings on Wednesday.
Source: Reuters/fs
Sign up for our newsletters
Get the CNA app
Stay updated with notifications for breaking news and our best stories
Get WhatsApp alerts
Join our channel for the top reads for the day on your preferred chat app
Get bite-sized news via a new
cards interface. Give it a try.
Click here to return to FAST
Tap here to return to FAST
FAST
